Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
IRTC iRhythm Technologies	$106.89 +0.2%	$103.99	$55.92 ▼ $128.52	$3.41B	1.45	458,775 shs	487,482 shs
SILK Silk Road Medical	$27.49	$27.31	$6.08 ▼ $27.51	$1.12B	1.53	1.20 million shs	N/A
SLNO Soleno Therapeutics	$74.86 -0.5%	$59.07	$36.93 ▼ $76.56	$3.74B	-2.29	728,218 shs	701,824 shs
TMDX TransMedics Group	$92.01 -0.5%	$75.41	$55.00 ▼ $177.37	$3.11B	2.14	1.35 million shs	747,092 shs

7 Energy Stocks to Buy and Hold Forever

With the proliferation of data centers and electric vehicles, the electric grid will only get more strained. Download this report to learn how energy stocks can play a role in your portfolio as the global demand for energy continues to grow.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
IRTC iRhythm Technologies	0.00%	+7.20%	+1.56%	-3.35%	-1.84%
SILK Silk Road Medical	0.00%	0.00%	0.00%	0.00%	+45.45%
SLNO Soleno Therapeutics	+2.21%	+5.42%	+4.56%	+52.49%	+65.32%
TMDX TransMedics Group	+2.48%	+1.34%	+34.78%	+41.05%	-4.96%

Compare MarketRank™

Company	Overall Score	Analyst's Opinion	Short Interest Score	ESG Score	News and Social Media Sentiment	Company Ownership	Earnings & Valuation
IRTC iRhythm Technologies	0.9848 of 5 stars	2.4	1.0	0.0	2.9	0.0	0.6
SILK Silk Road Medical	0.42 of 5 stars	0.9	0.0	4.3	0.6	0.0	0.6
SLNO Soleno Therapeutics	4.6443 of 5 stars	4.6	1.0	4.6	3.5	3.3	0.6
TMDX TransMedics Group	3.0296 of 5 stars	3.4	3.0	0.0	2.1	1.7	1.9

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
IRTC iRhythm Technologies	2.82	Moderate Buy	$119.73	12.01% Upside
SILK Silk Road Medical	1.80	Reduce	$24.00	-12.70% Downside
SLNO Soleno Therapeutics	3.20	Buy	$104.67	39.82% Upside
TMDX TransMedics Group	2.82	Moderate Buy	$124.20	34.99% Upside

Current Analyst Ratings Breakdown

Latest SILK, SLNO, IRTC, and TMDX Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
4/29/2025	TMDX TransMedics Group	Piper Sandler Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Overweight ➝ Overweight	$90.00 ➝ $105.00
4/24/2025	SLNO Soleno Therapeutics	Piper Sandler Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Price Target	Overweight ➝ Overweight	$93.00 ➝ $145.00
4/23/2025	TMDX TransMedics Group	Needham & Company LLC Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Hold ➝ Hold
4/15/2025	SLNO Soleno Therapeutics	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$100.00 ➝ $100.00
3/31/2025	SLNO Soleno Therapeutics	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Price Target	Buy ➝ Buy	$70.00 ➝ $100.00
3/28/2025	SLNO Soleno Therapeutics	Guggenheim Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$70.00 ➝ $81.00
3/28/2025	SLNO Soleno Therapeutics	Stifel Nicolaus Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Price Target	Buy ➝ Buy	$74.00 ➝ $108.00
3/27/2025	SLNO Soleno Therapeutics	UBS Group Subscribe to MarketBeat All Access for the recommendation accuracy rating	Set Price Target		$105.00
3/27/2025	SLNO Soleno Therapeutics	Laidlaw Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Price Target	Buy ➝ Buy	$75.00 ➝ $105.00
3/27/2025	SLNO Soleno Therapeutics	Cantor Fitzgerald Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Price Target	Overweight ➝ Overweight	$67.00 ➝ $123.00
3/27/2025	SLNO Soleno Therapeutics	Robert W. Baird Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Price Target	Outperform ➝ Outperform	$72.00 ➝ $102.00

(Data available from 4/30/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
IRTC iRhythm Technologies	$591.84M	5.76	N/A	N/A	$6.85 per share	15.60
SILK Silk Road Medical	$177.13M	6.31	N/A	N/A	$3.88 per share	7.09
SLNO Soleno Therapeutics	N/A	N/A	N/A	N/A	$5.16 per share	N/A
TMDX TransMedics Group	$441.54M	7.05	$0.17 per share	530.08	$4.20 per share	21.91

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
IRTC iRhythm Technologies	-$123.41M	-$3.64	N/A	N/A	N/A	-19.14%	-118.83%	-11.34%	5/1/2025 (Estimated)
SILK Silk Road Medical	-$55.74M	-$1.37	N/A	N/A	N/A	-29.53%	-37.30%	-21.57%	N/A
SLNO Soleno Therapeutics	-$38.99M	-$4.26	N/A	N/A	N/A	N/A	-61.99%	-55.21%	5/7/2025 (Estimated)
TMDX TransMedics Group	-$25.03M	$1.01	97.88	64.34	N/A	8.14%	18.74%	4.39%	5/8/2025 (Estimated)

Latest SILK, SLNO, IRTC, and TMDX Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
5/8/2025	Q1 2025	TMDX TransMedics Group	$0.29	N/A	N/A	N/A	$123.39 million	N/A
5/7/2025	Q1 2025	SLNO Soleno Therapeutics	-$1.08	N/A	N/A	N/A	N/A	N/A
5/1/2025	Q1 2025	IRTC iRhythm Technologies	-$0.89	N/A	N/A	N/A	$153.39 million	N/A
3/5/2025	Q4 2024	SLNO Soleno Therapeutics	-$0.86	-$1.27	-$0.41	-$1.27	N/A	N/A
2/20/2025	Q4 2024	IRTC iRhythm Technologies	-$0.29	$0.01	+$0.30	-$0.04	$158.30 million	$164.33 million

Compare Dividends

Company	Annual Payout	Dividend Yield	3-Year Dividend Growth	Payout Ratio	Years of Consecutive Growth
IRTC iRhythm Technologies	N/A	N/A	N/A	N/A	N/A
SILK Silk Road Medical	N/A	N/A	N/A	N/A	N/A
SLNO Soleno Therapeutics	N/A	N/A	N/A	N/A	N/A
TMDX TransMedics Group	N/A	N/A	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
IRTC iRhythm Technologies	9.00	6.27	6.12
SILK Silk Road Medical	0.49	7.63	6.69
SLNO Soleno Therapeutics	N/A	17.26	17.26
TMDX TransMedics Group	2.42	8.20	7.33

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
IRTC iRhythm Technologies	N/A
SILK Silk Road Medical	N/A
SLNO Soleno Therapeutics	97.42%
TMDX TransMedics Group	99.67%

Insider Ownership

Company	Insider Ownership
IRTC iRhythm Technologies	0.68%
SILK Silk Road Medical	3.90%
SLNO Soleno Therapeutics	12.30%
TMDX TransMedics Group	7.00%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
IRTC iRhythm Technologies	1,790	31.92 million	31.09 million	Optionable
SILK Silk Road Medical	410	40.63 million	37.91 million	Optionable
SLNO Soleno Therapeutics	30	49.91 million	37.81 million	Optionable
TMDX TransMedics Group	210	33.82 million	31.21 million	Optionable

SILK, SLNO, IRTC, and TMDX Headlines

Recent News About These Companies

TransMedics Group (NASDAQ:TMDX) Stock Price Down 5.1% - Here's Why

April 30 at 4:55 PM | marketbeat.com

First Light Asset Management LLC Decreases Stock Position in TransMedics Group, Inc. (NASDAQ:TMDX)

April 30 at 8:13 AM | marketbeat.com

Bronstein, Gewirtz & Grossman, LLC Announces an Investigation Against TransMedics Group, Inc. (TMDX) and Encourages Investors to Learn More About the Investigation

April 29 at 10:00 AM | accessnewswire.com

Raymond James Financial Inc. Makes New Investment in TransMedics Group, Inc. (NASDAQ:TMDX)

April 29 at 3:42 AM | marketbeat.com

TransMedics Group, Inc. (NASDAQ:TMDX) Receives Consensus Rating of "Moderate Buy" from Analysts

April 29 at 2:37 AM | marketbeat.com

TransMedics Group, Inc. (NASDAQ:TMDX) Shares Bought by Bullseye Asset Management LLC

April 27 at 7:34 AM | marketbeat.com

NewEdge Advisors LLC Purchases 11,406 Shares of TransMedics Group, Inc. (NASDAQ:TMDX)

April 26, 2025 | marketbeat.com

TransMedics Group (NASDAQ:TMDX) Receives "Hold" Rating from Needham & Company LLC

April 25, 2025 | marketbeat.com

Needham & Company LLC Reaffirms Hold Rating for TransMedics Group (NASDAQ:TMDX)

April 25, 2025 | americanbankingnews.com

Envestnet Asset Management Inc. Sells 5,911 Shares of TransMedics Group, Inc. (NASDAQ:TMDX)

April 25, 2025 | marketbeat.com

TransMedics to Report First Quarter 2025 Financial Results on May 8, 2025

April 24, 2025 | prnewswire.com

TransMedics Group, Inc. (TMDX) Investigation: Bronstein, Gewirtz & Grossman, LLC Encourages Stockholders to Contact the Firm to Learn More About the Investigation

April 24, 2025 | accessnewswire.com

1 Beaten-Down Stock to Buy Right Now and Hold for a Decade

April 24, 2025 | fool.com

TransMedics Group (TMDX) Projected to Post Earnings on Tuesday

April 24, 2025 | marketbeat.com

TransMedics Group (TMDX) Gets a Hold from Needham

April 23, 2025 | markets.businessinsider.com

TransMedics: Get Some Exposure Despite Market Concerns

April 23, 2025 | seekingalpha.com

TransMedics: Downgrading To Sell As Growth Hurdles Mount

April 22, 2025 | seekingalpha.com

Bronstein, Gewirtz & Grossman, LLC Announces an Investigation Against TransMedics Group, Inc. (TMDX) and Encourages Stockholders to Learn More About the Investigation

April 22, 2025 | accessnewswire.com

Barclays PLC Has $14.12 Million Holdings in TransMedics Group, Inc. (NASDAQ:TMDX)

April 22, 2025 | marketbeat.com

Wasatch Advisors LP Purchases 200,603 Shares of TransMedics Group, Inc. (NASDAQ:TMDX)

April 19, 2025 | marketbeat.com

LPL Financial LLC Purchases 5,223 Shares of TransMedics Group, Inc. (NASDAQ:TMDX)

April 19, 2025 | marketbeat.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

SILK, SLNO, IRTC, and TMDX Company Descriptions

iRhythm Technologies NASDAQ:IRTC

$106.89 +0.25 (+0.23%)

As of 04:00 PM Eastern

iRhythm Technologies, Inc., a digital healthcare company, engages in the design, development, and commercialization of device-based technology to provide ambulatory cardiac monitoring services to diagnose arrhythmias in the United States. It offers Zio services, an ambulatory monitoring solution, including long-term and short-term continuous monitoring and mobile cardiac telemetry monitoring services. The company also provides the Zio Monitor System, a prescription-only, remote electrocardiogram (ECG) monitoring system that consists of a patch ECG monitor that records the electric signal from the heart continuously for up to 14 days and the Zio ECG Utilization Software System, which supports the capture and analysis of ECG data recorded by the Zio Monitor patch at the end of the wear period, including specific arrhythmia events detected by the ZEUS System; the Zio XT System is the previous generation of the Zio Monitor System and is a prescription-only, remote ECG monitoring system that consists of the Zio XT patch that records the electric signal from the heart continuously for up to 14 days; and the Zio AT system, a prescription-only, remote ECG monitoring system that similarly consists of the Zio AT patch that records the electric signal from the heart continuously for up to 14 days and the ZEUS System, but which also incorporates the Zio AT wireless gateway that provides connectivity between the Zio AT patch and the ZEUS System during the patient wear period. It has a development collaboration agreement with Verily Life Sciences LLC and Verity Ireland Limited to develop various next-generation atrial fibrillation screening, detection, or monitoring products. The company was incorporated in 2006 and is headquartered in San Francisco, California.

Silk Road Medical NASDAQ:SILK

Silk Road Medical, Inc operates as a medical device company in the United States. The company offers various products for the treatment of carotid artery disease called transcarotid artery revascularization (TCAR). Its products comprise ENROUTE Transcarotid Neuroprotection System that is used to directly access the common carotid artery and establish temporary blood flow reversal; ENROUTE Transcarotid Stent System for transcarotid access; ENHANCE Transcarotid Peripheral Access Kit, which is used to gain initial access to the common carotid artery; ENROUTE 0.014 Guidewire for atraumatic vessel navigation and target lesion crossing for delivery of interventional devices; and ENROUTE Enflate Transcarotid RX Balloon Dilation Catheter, a transcarotid rapid exchange balloon for the TCAR procedure. The company was incorporated in 2007 and is headquartered in Sunnyvale, California.

Soleno Therapeutics NASDAQ:SLNO

$74.86 -0.41 (-0.54%)

As of 04:00 PM Eastern

Soleno Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of novel therapeutics for the treatment of rare diseases. Its lead candidate is Diazoxide Choline Extended-Release tablets, a once-daily oral tablet, which is in Phase III clinical trials for the treatment of Prader-Willi Syndrome. The company was formerly known as Capnia, Inc. and changed its name to Soleno Therapeutics, Inc. in May 2017. Soleno Therapeutics, Inc. was incorporated in 1999 and is based in Redwood City, California.

TransMedics Group NASDAQ:TMDX

$92.01 -0.42 (-0.45%)

As of 04:00 PM Eastern

TransMedics Group, Inc., a commercial-stage medical technology company, engages in transforming organ transplant therapy for end-stage organ failure patients in the United States and internationally. The company offers Organ Care System (OCS), a portable organ perfusion, optimization, and monitoring system that utilizes its proprietary and customized technology to replicate near-physiologic conditions for donor organs outside of the human body. Its OCS includes OCS LUNG for the preservation of standard criteria donor lungs for double-lung transplantation; OCS Heart, a technology for preservation of DBD donor hearts deemed unsuitable due to limitations of cold storage and for ex vivo reanimation, functional monitoring, and beating-heart preservation of donation-after-circulatory-death hearts; and OCS Liver for the preservation of DBD and DCD of donor livers. The company also developed national OCS program, a turnkey solution for outsourced organ retrieval; and provides OCS organ management and logistics services, including aviation and ground transportation, and other coordination activity. The company was founded in 1998 and is headquartered in Andover, Massachusetts.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time